Guangzhou Concord Cancer Center Surpasses 800 Patients, Reflecting Growing Demand for Precision Radiation Therapy in Asia
Guangzhou Concord Cancer Center Proton Therapy Center — one of the most advanced operational proton facilities in Asia, serving patients from 31 provinces and 20+ countries.
As of April 2026, the Proton Therapy Center at Guangzhou Concord Cancer Center has treated more than 800 patients, while daily treatment volume has exceeded 100 proton therapy sessions. Achieved within just 16 months of operation, this milestone represents one of the fastest clinical ramp-ups among newly launched proton therapy centers in the region.
The development also reflects expanding access to precision radiation oncology in South China, where demand for advanced cancer treatment technologies continues to increase.
In February 2025, the first group of patients completed proton therapy treatment at Guangzhou Concord Cancer Center. In the 16 months since, the center has not only exceeded 800 cumulative patients but also reached a sustained daily treatment volume of over 100 sessions — a throughput rate that ranks among the most productive proton centers in Asia.
From treatment planning to image-guided delivery — the precision workflow behind every proton therapy session at GCCC.
Proton therapy remains one of the most technologically advanced forms of radiation treatment available today, particularly for tumors located near critical organs and tissues. By utilizing the Bragg Peak effect, proton beams can deliver highly concentrated radiation doses to tumors while reducing exposure to surrounding healthy structures — significantly lowering the risk of damage to organs such as the heart, lungs, and spinal cord.
Varian ProBeam treatment room at GCCC — delivering Intensity-Modulated Proton Therapy (IMPT) with image-guided verification for patients across age groups and regions.
Guangzhou Concord Cancer Center is the first operational proton therapy center in South China and is equipped with the Varian Medical Systems ProBeam proton therapy system. The center includes four 360-degree rotating gantry treatment rooms and fully implements IMPT (Intensity-Modulated Proton Therapy) alongside image-guided verification technologies.
360-degree rotating gantry treatment room — one of four proton therapy rooms at GCCC.
Image-guided proton therapy in progress — precision delivery verified in real time.
With clinical guidance and quality management support from MD Anderson Cancer Center, the hospital has continued to align its proton therapy workflows and quality assurance systems with internationally recognized standards.
"The ProBeam system's precision and our IMPT capabilities allow us to treat complex tumors with unprecedented accuracy — while preserving surrounding healthy tissue. This is the core value of proton therapy in modern oncology." — GCCC Proton Therapy Clinical Team
The center's patient population reflects both the diversity and growing international demand for advanced radiation oncology services in Asia. Patients treated at the center come from all 31 provincial-level regions across China, as well as more than 20 countries and regions worldwide. Ages range from infants as young as 13 months to patients aged 91 years.
Patient Reach:
31 provinces across China — 100% national coverage
20+ countries and regions — including Indonesia, Bangladesh, Philippines, and the Middle East
Age range: 13 months (pediatric) to 91 years (geriatric)
International patients and their families receive personalized case management from dedicated coordinators at GCCC.
Cross-border coordination — GCCC's international patient team working with overseas medical partners to ensure seamless care pathways.
Patients of all ages and across a wide range of cancer types — from pediatric to geriatric, nasopharyngeal to prostate — receive precision proton therapy at GCCC.
International patients and families receiving coordinated care at Guangzhou Concord Cancer Center — supported by multilingual coordinators and dedicated case managers across 20+ countries.
Treatment indications include pediatric tumors, central nervous system tumors, nasopharyngeal carcinoma, lung cancer, esophageal cancer, breast cancer, liver cancer, prostate cancer, and soft tissue sarcomas. The growing number of international patients also reflects a broader trend in cross-border cancer care within Asia, where patients increasingly seek access to specialized technologies and multidisciplinary oncology expertise beyond their home countries.
GCCC's international patient lounge — designed to provide a comfortable, culturally sensitive environment for patients and families from around the world.
Beyond equipment installation, the ability to sustain high-volume proton therapy operations requires coordinated clinical workflows, multidisciplinary collaboration, and standardized patient management systems. According to hospital data, 97.7% of patients complete treatment as scheduled. The hospital utilizes a case management model to support patients throughout consultation, treatment planning, scheduling, treatment delivery, and follow-up care.
- 2017: Proton therapy project initiated at Guangzhou Concord Cancer Center
- Years following: Cyclotron installation, first beam delivery, clinical trials
- 2024: Regulatory approvals completed; clinical operation preparation finalized
- February 2025: First group of patients completed proton therapy treatment
- April 2026: 800+ patients treated; daily volume exceeds 100 sessions
GCCC's multidisciplinary clinical team — radiation oncologists, medical physicists, and specialist nurses working in coordinated case management workflows to ensure 97.7% on-schedule treatment completion.
The hospital's case management model ensures that each patient — whether from a neighboring province or across the globe — receives continuous, coordinated care from initial consultation through long-term follow-up. Multilingual support, international insurance direct billing, and dedicated patient coordinators are integral to this service model.
The rapid growth of proton therapy services at Guangzhou Concord Cancer Center reflects a broader shift in Asia's oncology landscape, where demand for precision medicine and advanced radiotherapy technologies continues to rise. Historically, access to proton therapy in Asia has been concentrated in a limited number of markets such as Japan and Singapore. The emergence of large-scale operational proton centers in mainland China may further expand regional treatment accessibility for both domestic and international patients.
GCCC's advanced proton therapy treatment planning system — enabling precise dose optimization and treatment scheduling for complex cases across Asia.
Growing Cross-Border Cancer Care Demand:
In 2025, major international hospitals in China received 12.8 million foreign patient visits — a 73.6% increase compared to three years earlier.
In Guangdong Province, inpatient demand from foreign patients increased by 76.05% year-on-year.
GCCC actively participates in international medical forums and cross-border healthcare partnerships — advancing precision oncology collaboration across Asia.
Guangzhou Concord Cancer Center — setting a new standard for precision radiation oncology and international patient care in South China and across Asia.
For many patients with complex or difficult-to-treat cancers, this development may offer additional treatment pathways within the region. Guangzhou Concord Cancer Center remains committed to expanding global access to high-quality cancer care, contributing to the growing ecosystem of international healthcare in Asia.